INOVIO PHARMACEUTICALS, INC. (INO)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue from collaborative arrangement | - | 65,343 | - | 100,762 |
| Research and development | 14,521,407 | 16,090,902 | 18,733,584 | 23,090,989 |
| General and administrative | 8,563,112 | 9,024,970 | 8,613,895 | 10,206,686 |
| Total operating expenses | 23,084,519 | 25,115,872 | 27,347,479 | 33,297,675 |
| Loss from operations | -23,084,519 | -25,050,529 | -27,347,479 | -33,196,913 |
| Interest income | 610,638 | 808,077 | 1,106,758 | - |
| Interest expense | - | - | - | - |
| Change in fair value of common stock warrant liability | 1,878,010 | -3,712,872 | - | - |
| Net unrealized gain (loss) on available-for-sale equity securities | 759,289 | 140,234 | 1,330,811 | -20,820 |
| Gain (loss) on investment in affiliated entity | 776,373 | 695,131 | 324,251 | -334,294 |
| Other (expense) income, net | -703,183 | -482 | -579,819 | 7,571 |
| Interest income | - | - | - | 1,307,358 |
| Net loss | -23,519,412 | -19,694,697 | -25,165,478 | -32,237,098 |
| Basic (in dollars per share) | -0.61 | -0.51 | -0.89 | -1.19 |
| Basic (in shares) | 38,830,053 | 38,613,653 | 28,140,497 | 27,197,802 |
| Diluted (in dollars per share) | -0.61 | -0.51 | -0.89 | -1.19 |
| Diluted (in shares) | 38,830,053 | 38,613,653 | 28,140,497 | 27,197,802 |